Larimar Therapeutics Advances Friedreich’s Ataxia Treatment After FDA Lifts Hold
BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) announced this week that the U.S. Food and Drug Administration (FDA) has removed the partial clinical hold on its nomlabofusp (CTI-1601) …
Larimar Therapeutics Advances Friedreich’s Ataxia Treatment After FDA Lifts Hold Read More